Drugs / BILR 355 BS
last change Sep 2007 re-read 2 minutes ago

BILR 355 BS

Developed for
HIV infectious disease
Investigated by
Boehringer Ingelheim

Trials 10 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT02259868 Jun → Sep 2005 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02256826 Apr → Jun 2005 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02253901 Mar → May 2005 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02257021 Feb → May 2005 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02256774 Oct 2004 → May 2005 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02253914 Feb → Dec 2004 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02257008 Mar → Dec 2003 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02253953 Nov 2002 → Dec 2003 Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT02254538 May 2002 → Feb 2003 Boehringer Ingelheim Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00294372 Feb 2006 → Sep 2007 HIV infectious disease Boehringer Ingelheim Terminated No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as BILR 355 BS ClinicalTrials.gov intervention name — accepted as the source's own label NCT02253953
9

NCT02257008

NCT02254538

NCT02253914

NCT02259868

NCT02256774

NCT02253901

NCT02257021

NCT00294372

NCT02256826

Route Oral oral administered” NCT00294372